Recombinant human erythropoietin in oncology: current status and further developments.

  title={Recombinant human erythropoietin in oncology: current status and further developments.},
  author={Andreas Engert},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  volume={16 10},
  • Andreas Engert
  • Published 2005 in
    Annals of oncology : official journal of the…
Anaemia effects up to 90% of cancer patients, with more than 60% requiring blood transfusion during or after treatment. With the advent of recombinant human erythropoietins (rHuEPO), an alternative to red blood cell transfusion has become available. So far, three drugs have been approved for the treatment of anaemia in patients with malignancies (epoetin alfa, epoetin beta and darbepoetin alfa). New concepts for the use of erythropoietin in cancer patients include 3- and 4-weekly dosing, as… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 13 extracted citations


Publications referenced by this paper.
Showing 1-10 of 79 references

Recombinant human erythropoietin in the treatment of the anaemia of cancer.

Acta haematologica • 1992
View 13 Excerpts
Highly Influenced

Randomized, doubleblind, placebo-controlled, dose-finding study of darbepoetin alfa administered once every 3 (Q3W) or 4 (Q4W) weeks in patients with solid tumours

D Kotasek, M Albertsson, J John Mackey
Proc Am Soc Clin Oncol • 2002
View 3 Excerpts
Highly Influenced

Chemotherapy-induced anemia in adults: incidence and treatment.

Journal of the National Cancer Institute • 1999
View 4 Excerpts
Highly Influenced

Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy

E Cortesi, A Mancuso, CA De Pasquale
Oncologist • 2004
View 2 Excerpts

Similar Papers

Loading similar papers…